Steven Moreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven Moreira has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Ana Vujovic
Division of Hematology, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado
136 shared publications - Kristin J. Hope
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
118 shared publications - Amanda Tajik
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
116 shared publications - Derek C. H. Chan
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada
116 shared publications - Emily Tsao
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada
116 shared publications - Lina Liu
Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
116 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
PLS-DA loadings from UHPLC/MS-based global metabolomic analysis data of HR-MDS (N=7) and healthy control (N=7) CD34+ HSPCs.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
PLS-DA loadings from UHPLC/MS-based global metabolomic analysis data of HR-MDS (N=7) and healthy control (N=7) CD34+ HSPCs.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S12 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Carbon flux metabolomic data obtained using UHPLC/MS from MDS-L cell line treated with DMSO or 100nM OT-82 for 24h and supplemented with 2.5mM 13C6-Glucose for the final 3h.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S12 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Carbon flux metabolomic data obtained using UHPLC/MS from MDS-L cell line treated with DMSO or 100nM OT-82 for 24h and supplemented with 2.5mM 13C6-Glucose for the final 3h.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S13 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Carbon and Nitrogen flux metabolomic data obtained using UHPLC/MS from MDS-L cell line treated with DMSO or 100nM OT-82 for 24h and supplemented with 0.5mM 13C515N2-Glutamine for the final 12h.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S13 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Carbon and Nitrogen flux metabolomic data obtained using UHPLC/MS from MDS-L cell line treated with DMSO or 100nM OT-82 for 24h and supplemented with 0.5mM 13C515N2-Glutamine for the final 12h.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
PLS-DA loadings from UHPLC/MS-based global metabolomic analysis data of MDS-L cell line treated with DMSO or 100nM OT-82 for 24h.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
PLS-DA loadings from UHPLC/MS-based global metabolomic analysis data of MDS-L cell line treated with DMSO or 100nM OT-82 for 24h.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Metabolite abundance obtained from UHPLC/MS-based global metabolomic analysis of MDS-L cell line treated with DMSO or 100nM OT-82 for 24h.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Metabolite abundance obtained from UHPLC/MS-based global metabolomic analysis of MDS-L cell line treated with DMSO or 100nM OT-82 for 24h.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Joint Pathway Analysis for global metabolomic and proteomic data comparing differentially expressed metabolites and protein in HR-MDS (N=7) and healthy control (N=7) CD34+ HSPCs.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Joint Pathway Analysis for global metabolomic and proteomic data comparing differentially expressed metabolites and protein in HR-MDS (N=7) and healthy control (N=7) CD34+ HSPCs.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Metabolite abundance obtained from UHPLC/MS-based global metabolomic analysis of HR-MDS (N=7) and healthy control (N=7) CD34+ HSPCs.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Metabolite abundance obtained from UHPLC/MS-based global metabolomic analysis of HR-MDS (N=7) and healthy control (N=7) CD34+ HSPCs.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S14 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Nitrogen flux metabolomic data obtained using UHPLC/MS from MDS-L cell line treated with DMSO or 100nM OT-82 for 24h and supplemented with 2mM 15N2-Tryptophan for the full 24h.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S14 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Nitrogen flux metabolomic data obtained using UHPLC/MS from MDS-L cell line treated with DMSO or 100nM OT-82 for 24h and supplemented with 2mM 15N2-Tryptophan for the full 24h.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Protein Enrichment Analysis for LC/MS-based global proteomic analysis data comparing differentially expressed protein in HR-MDS (N=7) versus healthy control (N=7) CD34+ HSPCs.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Protein Enrichment Analysis for LC/MS-based global proteomic analysis data comparing differentially expressed protein in HR-MDS (N=7) versus healthy control (N=7) CD34+ HSPCs.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Geneset Enrichment Analysis for microarray data (GSE19429) comparing differentially expressed genes in HR-MDS (N=183) versus healthy control (N=17) CD34+ HSPCs.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from The Nicotinamide Salvage Pathway Is a Metabolic Vulnerability of High-Risk MDS Stem Cells
Geneset Enrichment Analysis for microarray data (GSE19429) comparing differentially expressed genes in HR-MDS (N=183) versus healthy control (N=17) CD34+ HSPCs.